Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma.

Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ, Harousseau JL, Bataille R.

Blood. 2003 Aug 1;102(3):1070-1. Epub 2003 Apr 17.

PMID:
12702507
2.

Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma.

Moreau P, Misbahi R, Milpied N, Morineau N, Mahé B, Vigier M, Rapp MJ, Bataille R, Harousseau JL.

Leukemia. 2002 Sep;16(9):1838-43.

3.

Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells.

Le Gouill S, Pellat-Deceunynck C, Harousseau JL, Rapp MJ, Robillard N, Bataille R, Amiot M.

Leukemia. 2002 Sep;16(9):1664-7.

4.

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R, Amiot M.

Blood. 2002 Jul 1;100(1):194-9.

PMID:
12070027
5.

Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy.

Vigouroux S, Milpied N, Andrieu JM, Colonna P, Ifrah N, Colombat P, Desablens B, Abgrall JF, Casassus P, Guilhot F, Briere J, Le Mevel A, Moreau P, Mechinaud F, Mahe B, Morineau N, Vigier M, Rapp MJ, Harousseau JL.

Bone Marrow Transplant. 2002 May;29(10):833-42.

6.

[Primary cutaneous cryptococcosis in HIV-seronegative subjects].

Quéreux G, Milpied B, Morin O, Andrès P, Parant E, Poirier P, Rapp MJ, Stalder JF.

Ann Dermatol Venereol. 2001 Oct;128(10 Pt 1):1009-13. French.

7.

Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.

Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, Minvielle S, Bataille R; Intergroupe Francophone du Myélome.

Blood. 2002 Mar 15;99(6):2185-91.

PMID:
11877296
8.

Use of pathology-specific peripheral blood CD34 thresholds to predict leukapheresis CD34 content with optimal accuracy: a bicentric analysis of 299 leukaphereses.

Dobo I, Robillard N, Pineau D, Geneviève F, Piard N, Rapp MJ, Boasson M, Zandecki M, Hermouet S.

Ann Hematol. 2001 Nov;80(11):639-46.

PMID:
11757722
9.

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.

Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, Rapp MJ, Jaubert J, Autrand C, Divine M, Dreyfus B, Maloum K, Travade P, Dighiero G, Binet JL, Chastang C; French Cooperative Group on Chronic Lymphocytic Leukemia.

Blood. 2001 Oct 15;98(8):2319-25.

PMID:
11588025
10.

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.

Bezieau S, Devilder MC, Avet-Loiseau H, Mellerin MP, Puthier D, Pennarun E, Rapp MJ, Harousseau JL, Moisan JP, Bataille R.

Hum Mutat. 2001 Sep;18(3):212-24.

PMID:
11524732
11.

[Cryptococcus neoformans infection in hematologic malignancies].

Vigouroux S, Morin O, Milpied N, Mahé B, Rapp MJ, Harousseau JL.

Rev Med Interne. 2000 Nov;21(11):955-60. French.

PMID:
11109592
12.

Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation.

Barillé S, Bataille R, Rapp MJ, Harousseau JL, Amiot M.

J Immunol. 1999 Nov 15;163(10):5723-8.

13.

Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage.

Thabard W, Barillé S, Collette M, Harousseau JL, Rapp MJ, Bataille R, Amiot M.

Clin Cancer Res. 1999 Oct;5(10):2693-7.

14.
15.

Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma.

Moreau P, Milpied N, Mahé B, Juge-Morineau N, Rapp MJ, Bataille R, Harousseau JL.

Bone Marrow Transplant. 1999 May;23(10):1003-6.

16.

Familial multiple myeloma: report of fifteen families.

Grosbois B, Jego P, Attal M, Payen C, Rapp MJ, Fuzibet JG, Maigre M, Bataille R.

Br J Haematol. 1999 Jun;105(3):768-70.

PMID:
10354144
17.

Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy.

Puthier D, Pellat-Deceunynck C, Barillé S, Robillard N, Rapp MJ, Juge-Morineau N, Harousseau JL, Bataille R, Amiot M.

Leukemia. 1999 Feb;13(2):289-94.

18.

High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization.

Avet-Loiseau H, Brigaudeau C, Morineau N, Talmant P, Laï JL, Daviet A, Li JY, Praloran V, Rapp MJ, Harousseau JL, Facon T, Bataille R.

Genes Chromosomes Cancer. 1999 Jan;24(1):9-15.

PMID:
9892103
19.

High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.

Avet-Loiseau H, Li JY, Facon T, Brigaudeau C, Morineau N, Maloisel F, Rapp MJ, Talmant P, Trimoreau F, Jaccard A, Harousseau JL, Bataille R.

Cancer Res. 1998 Dec 15;58(24):5640-5.

20.

The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma.

Pellat-Deceunynck C, Barillé S, Jego G, Puthier D, Robillard N, Pineau D, Rapp MJ, Harousseau JL, Amiot M, Bataille R.

Leukemia. 1998 Dec;12(12):1977-82.

21.

High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience.

Milpied N, Gaillard F, Moreau P, Mahé B, Souchet J, Rapp MJ, Bulabois CE, Morineau N, Harousseau JL.

Bone Marrow Transplant. 1998 Oct;22(7):645-50.

22.

Ovarian transposition by laparoscopy before radiotherapy in the treatment of Hodgkin's disease.

Classe JM, Mahé M, Moreau P, Rapp MJ, Maisonneuve H, Lemevel A, Bourdin S, Harousseau JL, Cuillière JC.

Cancer. 1998 Oct 1;83(7):1420-4.

PMID:
9762944
23.

Early intensive therapy with autologous stem cell transplantation in high-risk Hodgkin's disease: long-term follow-up in 35 cases.

Moreau P, Milpied N, Rapp MJ, Moreau A, Bourdin S, Mahe MA, Dupas B, Le Tortorec S, Hamidou M, Maisoneuve H, Mahe B, Bulabois CE, Morineau N, Jardel H, Harousseau JL.

Leuk Lymphoma. 1998 Jul;30(3-4):313-24.

PMID:
9713963
24.

Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.

Moreau P, Milpied N, Voillat L, Colombat P, Mahé B, Rapp MJ, Moreau A, Dupas B, Bulabois CE, Juge-Morineau N, Harousseau JL.

Bone Marrow Transplant. 1998 Jun;21(12):1193-6.

25.

CD28, a marker associated with tumoral expansion in multiple myeloma.

Robillard N, Jego G, Pellat-Deceunynck C, Pineau D, Puthier D, Mellerin MP, Barillé S, Rapp MJ, Harousseau JL, Amiot M, Bataille R.

Clin Cancer Res. 1998 Jun;4(6):1521-6.

26.

Long-term results of total abdominopelvic irradiation in non-Hodgkin's lymphomas after failure of chemotherapy.

Mahé MA, Bourdin S, Le Mevel A, Moreau P, Moreau A, Hamidou M, Gaillard F, Rapp MJ, Milpied N, Harousseau JL.

Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):117-21.

PMID:
9588925
27.

Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells.

Barillé S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL, Bataille R, Amiot M.

Blood. 1997 Aug 15;90(4):1649-55.

PMID:
9269785
28.

[Acquired Willebrand syndrome with lymphoproliferative disorders].

Hamidou M, Agard C, Fressinaud E, Fiks-Sigaud M, Rapp MJ, Grolleau JY, Harousseau JL.

Presse Med. 1997 Jan 18-25;26(1):12-4. French.

PMID:
9082394
29.

A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity.

Moreau P, Kergueris MF, Milpied N, Le Tortorec S, Mahé B, Bulabois CE, Rapp MJ, Larousse C, Bataille R, Harousseau JL.

Br J Haematol. 1996 Dec;95(3):527-30.

PMID:
8943896
30.

13q14 deletions are not primary events in B-cell chronic lymphocytic leukemia: a study of 100 patients using fluorescence in situ hybridization.

Avet-Loiseau H, Devilder MC, Garand R, Bouyge I, Rapp MJ, Milpied N, Harousseau JL, Moisan JP, Bataille R.

Clin Cancer Res. 1996 Oct;2(10):1673-7.

31.

Successful allogeneic bone marrow transplantation for early relapse after autologous bone marrow transplantation in two cases of aggressive high-grade non-Hodgkin's lymphoma.

Moreau P, Méchinaud F, Mahé B, Le Tortorec S, Rapp MJ, Maisonneuve H, Harousseau JL, Milpied N.

Bone Marrow Transplant. 1996 Sep;18(3):665-7.

PMID:
8879639
32.

G-CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma.

Mahé B, Milpied N, Hermouet S, Robillard N, Moreau P, Letortorec S, Rapp MJ, Bataille R, Harousseau JL.

Br J Haematol. 1996 Feb;92(2):263-8.

PMID:
8602984
33.

High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells.

Juge-Morineau N, Mellerin MP, Francois S, Rapp MJ, Harousseau JL, Amiot M, Bataille R.

Br J Haematol. 1995 Nov;91(3):664-7.

PMID:
8555072
34.

Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization.

Pellat-Deceunynck C, Barillé S, Puthier D, Rapp MJ, Harousseau JL, Bataille R, Amiot M.

Cancer Res. 1995 Aug 15;55(16):3647-53.

35.

An interleukin 1 receptor antagonist blocks the IL-1-induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma.

Lu ZY, Bataille R, Poubelle P, Rapp MJ, Harousseau JL, Klein B.

Stem Cells. 1995 Aug;13 Suppl 2:28-34.

PMID:
8520508
36.

Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.

Wu DP, Milpied N, Moreau P, Mechinaud-Lacroix F, Mahe B, Le Tortorec S, Rapp MJ, Bourdin S, Mahe JM, Harousseau JL.

Bone Marrow Transplant. 1994 Nov;14(5):751-7.

PMID:
7889008
37.

Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells.

Pellat-Deceunynck C, Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge-Morineau N, Wijdenes J, Amiot M.

Blood. 1994 Oct 15;84(8):2597-603.

PMID:
7522634
38.

Early intensive therapy with autotransplantation for high-risk Hodgkin's disease.

Moreau P, Milpied N, Mechinaud-Lacroix F, Mahe B, Rapp MJ, Le Tortorec S, Bourdin S, Dupas B, Harousseau JL.

Leuk Lymphoma. 1993 Dec;12(1-2):51-8.

PMID:
7512854
39.

Hb Saint Nazaire (beta 103[G5]Phe-->Ile): a new example of polycythemia due to a hemoglobin variant with increased oxygen affinity.

Wajcman H, Kister J, M'Rad A, Promé D, Milpied N, Rapp MJ, Harousseau JL, Riou J, Bardakdjian J, Galacteros F.

Am J Hematol. 1993 Sep;44(1):16-21.

PMID:
8342560
40.

[Drug interaction implicating miconazole in gel form and fluindione].

Ponge T, Rapp MJ, Fruneau P, Ponge A, Wassen-Hove L, Larousse C, Cottin S.

Therapie. 1987 Jul-Aug;42(4):412-3. French. No abstract available.

PMID:
3686478
41.

[Therapeutic leukapheresis in tricholeukocytic leukemia].

Karsenty G, Andreu G, Rapp MJ, Charron D, Binet JL.

Ann Med Interne (Paris). 1984;135(6):449-51. French.

PMID:
6508049

Supplemental Content

Support Center